Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura F.J. Huiskamp"'
Autor:
Laura Molenaar-Kuijsten, Laura F.J. Huiskamp, Remco de Bree, Lot A. Devriese, Alwin D. R. Huitema, Najiba Chargi
Publikováno v:
European Journal of Cancer. 160:92-99
BACKGROUND Locally advanced head and neck squamous cell carcinoma (HNSCC) is commonly treated with cisplatin-based chemoradiotherapy (CRT). Cisplatin is associated with severe toxicity, which negatively affects survival. In recent years, a relationsh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f23c630c7e9289f39e24bea72dec69
https://doi.org/10.1016/j.ejca.2021.10.010
https://doi.org/10.1016/j.ejca.2021.10.010
Publikováno v:
European Archives of Oto-Rhino-Laryngology
Purpose This study aims to investigate the predictive value of low skeletal muscle mass (SMM) for cetuximab dose-limiting toxicity (DLT) and its prognostic value in head and neck squamous cell carcinoma (HNSCC) patients treated with concomitant cetux
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c00b4b81eec9e4fd85a60861bb34b4
https://doi.org/10.1007/s00405-020-05972-2
https://doi.org/10.1007/s00405-020-05972-2
Autor:
Remco de Bree, Alwin D. R. Huitema, Laura F.J. Huiskamp, Anne M May, Lot A. Devriese, Najiba Chargi
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 3780, p 3780 (2020)
Journal of Clinical Medicine
Volume 9
Issue 11
Journal of Clinical Medicine
Volume 9
Issue 11
Low skeletal muscle mass (LSMM) is increasingly recognized for its predictive value for adverse events in cancer patients. In specific, the predictive value of LSMM has been demonstrated for anti-cancer drug toxicity in a variety of cancer types and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc2ccdc9fd075359960dbb844d9f0da
https://www.mdpi.com/2077-0383/9/11/3780
https://www.mdpi.com/2077-0383/9/11/3780
Autor:
Chargi N; Department of Head and Neck Surgical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands., Molenaar-Kuijsten L; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Huiskamp LFJ; Department of Head and Neck Surgical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands., Devriese LA; Department of Medical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands., de Bree R; Department of Head and Neck Surgical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands. Electronic address: R.deBree@umcutrecht.nl., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Jan; Vol. 160, pp. 92-99. Date of Electronic Publication: 2021 Nov 19.